Mylan Institutional, Inc. recalls Levothyroxine Sodium Tablets
- Published
- 26 Mar 2025
- Units affected
- 2 products
- Agency
- FDA
- Country
- United States
The hazard
Super-Potent Drug: Out of specification potency results were obtained.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), Rx Only, 100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each) per carton, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Made in India, NDC 51079-443-20.
Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), Rx Only, 100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each) per carton, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Made in India, NDC 51079-445-20.
- Brand / company
- Mylan Institutional, Inc.
- Codes / lots
- Lot 3115773, Exp. 03/31/2025 | Lot 3116074, Exp. 09/30/2025
- Distribution
- Nationwide in the USA
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 26 Mar 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.